Tacrolimus (-)-(1R, 9S, 12S, 13R, 14S, 17R, 18E, 21S, 23S, 24R, 25S, 27R)-17-Allyl-1, 14-dihydroxy-12[(E)-2-[(1R, 3R, 4R)-4hydroxy-3-methxoycylohexyl]-1-methylvinyl]-23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11, 28-dioxa-4-azatricyclo[22.3.1.04.9]octacos-18-ene-2, 3, 10, 16-tetrone hydrate
|
Antifungal agents (eg, clotrimazole, fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole), bromocriptine, calcium channel blockers (eg, diltiazem, felodipine, nicardipine, nifedipine, verapamil), chloramphenicol, cimetidine, cisapride, cyclosporine, danazol, ethinyl estradiol, fosphenytoin, lansoprazole, macrolide antibiotics (eg, clarithromycin, erythromycin, troleandomycin), magnesium-aluminum hydroxide, methylprednisolone, metoclopramide, metronidazole, nefazodone, omeprazole, protease inhibitors (eg, indinavir, ritonavir, saquinavir), telithromycin, theophylline Tacrolimus blood concentrations may be elevated, increasing the risk of toxicity.
Carbamazepine, caspofungin, phenobarbital, phenytoin, prednisolone, prednisone, rifabutin, rifampin, sirolimus, St. John's wort Tacrolimus blood concentrations may be reduced, increasing the risk of transplant rejection.
Cyclosporine Additive nephrotoxicity.
CYP3A4 inhibitors (eg, cimetidine, erythromycin, ketoconazole) Use with caution during topical administration.
Ethanol Risk of facial flushing may be increased with topical tacrolimus.
Hydantoins (eg, phenytoin) Tacrolimus plasma levels may be reduced, while hydantoin concentrations may be increased.
Mycophenolate mofetil, sildenafil, simvastatin Plasma levels may be elevated by tacrolimus, increasing the risk of adverse reactions.
Vaccination (eg, BCG, measles, mumps, oral polio, rubella, TY 21a typhoid, yellow fever) Vaccination may be less effective. Avoid use of live vaccines.
Ziprasidone Risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased. Coadministration is contraindicated.
|